Global Life Science Business Partnering (GLSBP) - January 2025

Highlights of Deals in January-2025

1.     PE Investor Quadria Capital to invest US$100 Million in CDMO Aragen for minority stake.

2.     Reliance acquires Karkinos Healthcare for INR 375 crore(~US$ 45 Million).

3.     Sun Pharma's unit Taro to acquire 100% stake in Antibe Therapeutics of Canada.

4.     Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences.

5.     Lupin acquires Eli Lilly’s branded Insulin in India.

6.     Zydus Lifesciences joins hands with CVS Caremark for diabetes drugs template formulary.

7.     Roche inks co-development pact with Innovent Biologics for novel cancer drug; will pay US$ 80 Million as upfront to Innovent.

8.     GEON Performance Solutions acquires Foster Corporation.

9.     Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical.

10.  Iconovo and Lonza to collaborate on formulation development of an intranasal biologic.

11.  Synaffix and Mitsubishi Tanabe Pharma ink license agreement for ADC technology

12.  Heraeus acquires Umicore’s Platinum API business outside of South America.

13.  Syensqo partners with MezLight to launch the world’s first sterile reusable surgical task light.

14.  Gilead, LEO Pharma partner to develop programs for inflammatory diseases.

 

Aagami Updates:

1.     Aagami CEO Dinesh Jain had a very fruitful JPM Week 2025 including Biotech Showcase in San Francisco (January 12-16). During the week, Dinesh had over 45 strategic one-on-one meetings with key decision-makers in the Biopharma industry.

2.     Aagami has received a new assignment from an existing client, for supporting them in for deal structuring and negotiations with a Large Global Biopharma company.

3.     Our CEO Dinesh Jain (based in Naperville, Illinois) is visiting India for a month, starting Feb 04th.

4.     We are glad to announce that Aagami will be attending DCAT week in New York (March 17-20). If you are also attending, please contact us to set up a meeting to explore new possibilities.

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses. Also, Phase 2 trials are starting in Central Africa for MPOX.

2.     Licensing: Several Biosimilars available for Partnering in Japan

a.     Denosumab (Prolia® & Xgeva®)

b.     Romiplostim (Nplate®) [ For immune thrombocytopenia (ITP) ]

c.     Teriparatide (Forteo®/Forsteo®) [ For Osteoporosis ]  

3.     Seeking Acquisition /JV – Clinical stage Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia [Second Human Trial (n=30) ongoing in AU]. Now Leveraging latest in AI.

  1. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – For 1) Depression and ALS 2) Anti-Obesity.

For Acquisition:

1.    Lucrative Opportunity to acquire IP Portfolio (low pricing) of clinical stage First-in-Class Non-Opioid Analgesic.

2.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

3.     US IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).

4.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU). Now Leveraging the Latest in AI.

Seeking Investment:

  1. Market Ready Nutra portfolio of US client leveraging the latest in AI; Offering stake for $25 Million.
  2. Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications, seeking $10 Million.
  3. Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – 1. For Depression and ALS 2. Anti-Obesity. Presently seek $9 Million
  4. Engineering Therapeutics to Block Pathogenic Autoantibodies: Currently Need $6M seed to:
    1. GLP-tox studies
    2. First-in-human trials
    3. Phase II ready Series A raise

Specialized Services

1.     Oligonucleotide and peptides specialist Japanese CDMO for one stop solution to accelerate R&D.

2.     In vivo pharmacology specialists (Mirimus) - Your new partner in Drug Discovery.

Hope you found the content useful. We welcome your feedback and queries.

×
Twitter